



Insights Into Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Central

Virtual Platform


March 23, 2022

Insights From National Community Oncologists

How to Navigate This Report



Click to move to topic of interest or ARS supporting data



Click to return to previous slide

Topic	
Report Objectives	
Report Snapshot	
<ul style="list-style-type: none">• Session overview• Attendee overview• Agenda	
Topline Takeaways and Strategic Recommendations	
Key Insights and Discussion Summary	
<ul style="list-style-type: none">• First-line therapy for mCRPC• First-line discussion overview• Subsequent management for mCRPC• Subsequent-line discussion overview	
Advisor Key Takeaways	
ARS Data	

STUDY OBJECTIVES

To gain advisors' perspectives on

- > Current treatment practices regarding first-line treatment of metastatic castration-resistant prostate cancer (mCRPC)
- > Management of progressive mCRPC

Report Snapshot: Session Overview



A moderated roundtable discussion was held with oncologists in the Central region of the United States in a virtual setting on **March 23, 2022**

Disease-state and data presentations were led by **Dr Scott Tagawa** from Weill Cornell Medical Center, in conjunction with content developed by the Aptitude Health clinical team

Insights were obtained on **first-line and subsequent therapies for mCRPC** in the community and their impact on patient management


Data collection was accomplished through use of audience response system (ARS) questioning and in-depth moderated discussion

Report Snapshot: Attendee Overview



> The group of advisors comprised 10 oncologists from the Central region of the United States

INSTITUTION	CITY	STATE
Cancer Center of Kansas	Wichita	KS
Highlands Oncology Group	Springdale	AR
Texas Oncology	Dallas	TX
CHRISTUS Ochsner Oncology Clinic	Lake Charles	LA
Hendrick Cancer Center	Abilene	TX
Texas Oncology	Houston	TX
The Center for Cancer and Blood Disorders	Irving	TX
Mercy	Oklahoma City	OK
Texas Oncology	Palestine	TX
The Center for Cancer and Blood Disorders	Weatherford	TX



Report Snapshot: Agenda



Time (ET)	Topic
6.00 PM – 6.15 PM (15 min)	Introduction and ARS Questions <ul style="list-style-type: none">• Program overview and objectives• ARS questions
6.15 PM – 6.50 PM (35 min)	Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) <ul style="list-style-type: none">• Overview of current data
6.50 PM – 7.50 PM (60 min)	Moderated Discussion
7.50 PM – 8.00 PM (10 min)	Key Takeaways and Meeting Evaluation



Key Insights and Discussion Summary

FIRST-LINE TREATMENT – INSIGHTS AND DATA

“Mostly it’s like a clinical decision in my opinion and we go with docetaxel for a fast response but I think this might

1. Treatment outcomes in mCRPC (1/3)

The overall survival benefit was not significant. This is not necessarily surprising because this is a complex disease, so we need a good control. I think we need to be careful with the control group. I think we need to be careful with the control group. I think we need to be careful with the control group. I think we need to be careful with the control group.

2. Data needed to confirm that docetaxel is beneficial

That of all, a lot of things have been done, nothing is really new. I think we need to be careful with the control group. I think we need to be careful with the control group. I think we need to be careful with the control group. I think we need to be careful with the control group.

FIRST-LINE TREATMENT – INSIGHTS AND DATA

“We do have a genetic counselor . . . we use Myriad for all these things . . . mostly it has been tissue biopsies.”

1. Treatment success in prostate mCRPC

The overall survival benefit was not significant. This is not necessarily surprising since it is a complex disease, so we need overall survival. I would not use a significant endpoint like PSA, but I would use PSA as a secondary endpoint. PSA is a surrogate of overall survival, but the treatment, and overall drug, that is being evaluated.

2. Data needed to support from mCRPC in prostate

What are all the things that have been done, nothing is better than mCRPC and PSA. The overall survival with PSA is not significant. I would use a PSA endpoint. I would not use PSA as a surrogate for overall survival, but I would use PSA as a secondary endpoint. PSA is a surrogate of overall survival, but the treatment, and overall drug, that is being evaluated. I would use PSA as a secondary endpoint. PSA is a surrogate of overall survival, but the treatment, and overall drug, that is being evaluated.

SUBSEQUENT TREATMENT – INSIGHTS AND DATA

“We’re doing PSMA PETs, and the problem was we had to get the radio-isotope. Sometimes the half-life is at 3

1. Treatment success in patients with mCRPC

The overall survival benefit was not clear. This is not necessarily because there is no benefit, but it may be because of the way the data was analyzed. I think what we need to do is to look at the overall survival benefit in terms of the overall survival benefit. I think what we need to do is to look at the overall survival benefit in terms of the overall survival benefit. I think what we need to do is to look at the overall survival benefit in terms of the overall survival benefit.

2. Data needed to confirm that PSMA is beneficial

What are all the things that we need to know? We need to know the overall survival benefit. We need to know the overall survival benefit.

SUBSEQUENT TREATMENT – INSIGHTS AND DATA

“If you don’t have your diagnostic suite set up, I mean you have to build the suite. You have to get the radio

1. Treatment outcomes in patients with mCRPC

The overall survival benefit was not significant. This is not necessarily surprising because this is a complex disease, so we need overall survival. I would not use a treatment approach unless there is a clear benefit. I would not use a treatment approach unless there is a clear benefit. I would not use a treatment approach unless there is a clear benefit. I would not use a treatment approach unless there is a clear benefit.

2. Data needed to support from mCRPC in prostate

What are all the things that have been done? Nothing is better than docetaxel and enzalutamide. The overall survival with docetaxel and enzalutamide is not significant. I would not use a treatment approach unless there is a clear benefit. I would not use a treatment approach unless there is a clear benefit. I would not use a treatment approach unless there is a clear benefit. I would not use a treatment approach unless there is a clear benefit.



Advisor Key Takeaways

Advisor Key Takeaways



ADVISOR

> Re-emphasized the importance of using cabazitaxel

- There is a better understanding of sequencing therapy
- Really want to talk further with professional and understand how we have a better understanding of these drugs and have a better idea of when to use them in my practice

- There is a better understanding of some of my other options
- It's particularly important in the cabazitaxel and how the side effect would be managed in a second-line option for my own elderly patients
- There is a lot more emphasis on sequenced therapy and to things the professional that may offer some side effects

• It was good to hear about innovations and what's coming down the pipeline for immunotherapy

- There is a lot of good options for second-line that just look like you manage with second-line other profile and good response rate
- Sequencing is an issue

ADVISOR

> Learned about different PET scans and their uses

- The immunotherapy, adding the use to have different options besides PD-1 and what is going to come?

- The hope is that some of these immunotherapy agents will get added into frontline and hopefully improve the look up

- It's interesting to learn about all these immunotherapy treatments, especially the specific antibodies
- A lot of options coming up in the future. The only issue will be to learn how to sequence these drugs

- Not too much in the pipeline



Insights Into Metastatic Castration-Resistant Prostate Cancer

ARS Results: First-Line Treatment of
mCRPC

All Advisors See Patients With Advanced Prostate Cancer. For 60% of the Advisors This Is Less Than 20% of Their Total Patient Population (N = 10)

FOR EXAMPLE PURPOSES ONLY

Almost 90% of Advisors Declared More Than 20% of Their Patients With Advanced Prostate Cancer Have Metastatic Disease (n = 9*)

FOR EXAMPLE PURPOSES ONLY

*One advisor did not respond.



All Advisors Refer More Than 25% of Their Patients With mCRPC for Germline and Somatic Testing (n = 9*)

What proportion of your mCRPC patients do you refer for germline and somatic

FOR EXAMPLE PURPOSES ONLY



Seventy Percent of the Advisors Have Access to a Hot Lab/Theranostics Department in Their Practice (N = 10)

What service lines are currently available within your practice to support the treatment of

FOR EXAMPLE PURPOSES ONLY



About 78% of the Advisors Would Select Docetaxel for a Patient With mCRPC With Symptomatic Visceral Metastases Previously Treated With ADT + an AR-Targeted Agent (n = 9*)

FOR EXAMPLE PURPOSES ONLY

*One advisor did not respond.



Half the Advisors Would Recommend an AR-Targeted Agent for a Patient With mCRPC With Asymptomatic Bone-Only Metastases Previously Treated With ADT (N = 10)

FOR EXAMPLE PURPOSES ONLY



Two-Thirds of the Advisors Would Recommend an AR-Targeted Agent for a Patient With mCRPC With Symptomatic Bone and Visceral Metastases Previously Treated With ADT-Docetaxel (n = 9*)

FOR EXAMPLE PURPOSES ONLY





Insights Into Metastatic Castration-Resistant Prostate Cancer

ARS Results: Management of Progressive mCRPC

Patient Scenario 1

> What would be your preferred therapy for a patient with previously treated mCRPC

1. Enzalutamide

While the Majority of Advisors Would Utilize Cabazitaxel ± Carboplatin in This Scenario, 20% Would Choose a Trial of 177Lu-PSMA-617 (N = 10)

FOR EXAMPLE PURPOSES ONLY



Patient Scenario 2

> What would be your preferred therapy for a patient with previously treated mCRPC

1. Enzalutamide
2. Apalutamide
3. Metastatic castration-resistant prostate cancer (mCRPC) treatment options

One-Third of Advisors Would Choose Radium-223 in This Case Scenario (n = 9*)



FOR EXAMPLE PURPOSES ONLY

*One advisor did not respond.



While Half the Advisors Would Recommend Cabazitaxel ± Carboplatin for This Patient, 40% Would Choose a Trial of 177Lu-PSMA-617 (N = 10)

FOR EXAMPLE PURPOSES ONLY



US Headquarters

5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Headquarters

Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

[apptitudehealth.com](https://www.apptitudehealth.com)

